BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5(2): 125-133 [PMID: 24829859 DOI: 10.5306/wjco.v5.i2.125] [Cited by in CrossRef: 75] [Cited by in F6Publishing: 67] [Article Influence: 10.7] [Reference Citation Analysis]
Number Citing Articles
1 Kalimutho M, Parsons K, Mittal D, López JA, Srihari S, Khanna KK. Targeted Therapies for Triple-Negative Breast Cancer: Combating a Stubborn Disease. Trends Pharmacol Sci 2015;36:822-46. [PMID: 26538316 DOI: 10.1016/j.tips.2015.08.009] [Cited by in Crossref: 159] [Cited by in F6Publishing: 155] [Article Influence: 26.5] [Reference Citation Analysis]
2 Garona J, Pifano M, Pastrian MB, Gomez DE, Ripoll GV, Alonso DF. Addition of vasopressin synthetic analogue [V(4)Q(5)]dDAVP to standard chemotherapy enhances tumour growth inhibition and impairs metastatic spread in aggressive breast tumour models. Clin Exp Metastasis 2016;33:589-600. [PMID: 27146156 DOI: 10.1007/s10585-016-9799-5] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.4] [Reference Citation Analysis]
3 Braicu C, Pileczki V, Pop L, Petric RC, Chira S, Pointiere E, Achimas-Cadariu P, Berindan-Neagoe I. Dual targeted therapy with p53 siRNA and Epigallocatechingallate in a triple negative breast cancer cell model. PLoS One 2015;10:e0120936. [PMID: 25849487 DOI: 10.1371/journal.pone.0120936] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
4 Claude-Taupin A, Fonderflick L, Gauthier T, Mansi L, Pallandre JR, Borg C, Perez V, Monnien F, Algros MP, Vigneron M, Adami P, Delage-Mourroux R, Peixoto P, Herfs M, Boyer-Guittaut M, Hervouet E. ATG9A Is Overexpressed in Triple Negative Breast Cancer and Its In Vitro Extinction Leads to the Inhibition of Pro-Cancer Phenotypes. Cells 2018;7:E248. [PMID: 30563263 DOI: 10.3390/cells7120248] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
5 Liao MJ, Ye MN, Zhou RJ, Sheng JY, Chen HF. Yiqi formula enhances the antitumor effects of erlotinib for treatment of triple-negative breast cancer xenografts. Evid Based Complement Alternat Med 2014;2014:628712. [PMID: 25389442 DOI: 10.1155/2014/628712] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
6 Lee YR, Park MS, Joo HK, Kim KM, Kim J, Jeon BH, Choi S. Therapeutic positioning of secretory acetylated APE1/Ref-1 requirement for suppression of tumor growth in triple-negative breast cancer in vivo. Sci Rep 2018;8:8701. [PMID: 29880821 DOI: 10.1038/s41598-018-27025-9] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
7 Bhattacharya R, Banerjee K, Mukherjee N, Sen M, Mukhopadhyay A. From molecular insight to therapeutic strategy: The holistic approach for treating triple negative breast cancer. Pathology - Research and Practice 2017;213:177-82. [DOI: 10.1016/j.prp.2017.01.001] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
8 Katanaev VL, Blagodatski A, Xu J, Khotimchenko Y, Koval A. Mining Natural Compounds to Target WNT Signaling: Land and Sea Tales. Handb Exp Pharmacol 2021;269:215-48. [PMID: 34455487 DOI: 10.1007/164_2021_530] [Reference Citation Analysis]
9 Li H, Xu F, Gao G, Gao X, Wu B, Zheng C, Wang P, Li Z, Hua H, Li D. Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer. Redox Biol 2020;34:101564. [PMID: 32403079 DOI: 10.1016/j.redox.2020.101564] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 10.0] [Reference Citation Analysis]
10 Chun KH, Park JH, Fan S. Predicting and Overcoming Chemotherapeutic Resistance in Breast Cancer. Adv Exp Med Biol 2017;1026:59-104. [PMID: 29282680 DOI: 10.1007/978-981-10-6020-5_4] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 8.3] [Reference Citation Analysis]
11 Yao H, He G, Yan S, Chen C, Song L, Rosol TJ, Deng X. Triple-negative breast cancer: is there a treatment on the horizon? Oncotarget 2017;8:1913-24. [PMID: 27765921 DOI: 10.18632/oncotarget.12284] [Cited by in Crossref: 143] [Cited by in F6Publishing: 138] [Article Influence: 47.7] [Reference Citation Analysis]
12 Wawruszak A, Luszczki JJ, Kalafut J, Okla K, Halasa M, Rivero-Muller A, Stepulak A. Additive Pharmacological Interaction between Cisplatin (CDDP) and Histone Deacetylase Inhibitors (HDIs) in MDA-MB-231 Triple Negative Breast Cancer (TNBC) Cells with Altered Notch1 Activity-An Isobolographic Analysis. Int J Mol Sci 2019;20:E3663. [PMID: 31357442 DOI: 10.3390/ijms20153663] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 6.0] [Reference Citation Analysis]
13 Kim H, Cho J, Kwon SY, Kang SH. Biologic subtype is a more important prognostic factor than nodal involvement in patients with stages I and II breast carcinoma. Ann Surg Treat Res 2016;90:1-9. [PMID: 26793686 DOI: 10.4174/astr.2016.90.1.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
14 Torres-pérez SA, Ramos-godínez MDP, Ramón-gallegos E. Glycosylated one-step PAMAM dendrimers loaded with methotrexate for target therapy in breast cancer cells MDA-MB-231. Journal of Drug Delivery Science and Technology 2020;58:101769. [DOI: 10.1016/j.jddst.2020.101769] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 5.0] [Reference Citation Analysis]
15 Li S, Wu Y, Ding F, Yang J, Li J, Gao X, Zhang C, Feng J. Engineering macrophage-derived exosomes for targeted chemotherapy of triple-negative breast cancer. Nanoscale 2020;12:10854-62. [PMID: 32396590 DOI: 10.1039/d0nr00523a] [Cited by in Crossref: 35] [Cited by in F6Publishing: 21] [Article Influence: 35.0] [Reference Citation Analysis]
16 Reddy TP, Choi DS, Anselme AC, Qian W, Chen W, Lantto J, Horak ID, Kragh M, Chang JC, Rosato RR. Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs. Breast Cancer Res 2020;22:48. [PMID: 32414394 DOI: 10.1186/s13058-020-01280-z] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
17 Ebrahim HY, Mohyeldin MM, Hailat MM, El Sayed KA. (1S,2E,4S,7E,11E)-2,7,11-Cembratriene-4,6-diol semisynthetic analogs as novel c-Met inhibitors for the control of c-Met-dependent breast malignancies. Bioorg Med Chem 2016;24:5748-61. [PMID: 27681240 DOI: 10.1016/j.bmc.2016.09.032] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Olow AK, Veer LV', Wolf DM. Toward developing a metastatic breast cancer treatment strategy that incorporates history of response to previous treatments. BMC Cancer 2021;21:212. [PMID: 33648460 DOI: 10.1186/s12885-021-07912-7] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Wawruszak A, Luszczki J, Halasa M, Okon E, Landor S, Sahlgren C, Rivero-Muller A, Stepulak A. Sensitization of MCF7 Cells with High Notch1 Activity by Cisplatin and Histone Deacetylase Inhibitors Applied Together. Int J Mol Sci 2021;22:5184. [PMID: 34068438 DOI: 10.3390/ijms22105184] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
20 Nam K, Son SH, Oh S, Jeon D, Kim H, Noh DY, Kim S, Shin I. Binding of galectin-1 to integrin β1 potentiates drug resistance by promoting survivin expression in breast cancer cells. Oncotarget 2017;8:35804-23. [PMID: 28415760 DOI: 10.18632/oncotarget.16208] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 6.7] [Reference Citation Analysis]
21 Dubois C, Dufour R, Daumar P, Aubel C, Szczepaniak C, Blavignac C, Mounetou E, Penault-Llorca F, Bamdad M. Development and cytotoxic response of two proliferative MDA-MB-231 and non-proliferative SUM1315 three-dimensional cell culture models of triple-negative basal-like breast cancer cell lines. Oncotarget 2017;8:95316-31. [PMID: 29221130 DOI: 10.18632/oncotarget.20517] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
22 Ye F, He M, Huang L, Lang G, Hu X, Shao Z, Di G, Cao A. Insights Into the Impacts of BRCA Mutations on Clinicopathology and Management of Early-Onset Triple-Negative Breast Cancer. Front Oncol 2020;10:574813. [PMID: 33505905 DOI: 10.3389/fonc.2020.574813] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
23 Das S, Tripathi N, Siddharth S, Nayak A, Nayak D, Sethy C, Bharatam PV, Kundu CN. Etoposide and doxorubicin enhance the sensitivity of triple negative breast cancers through modulation of TRAIL-DR5 axis. Apoptosis 2017;22:1205-24. [DOI: 10.1007/s10495-017-1400-4] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
24 Elshaflu H, Bjelogrlić S, Muller CD, Todorović TR, Rodić M, Marinković A, Filipović NR. Co(III) complex with ( E )-2-(2-(pyridine-2-ylmethylene)hydrazinyl)-4-(4-tolyl)-1,3-thiazole: structure and activity against 2-D and 3-D cancer cell models. Journal of Coordination Chemistry 2016;69:3354-66. [DOI: 10.1080/00958972.2016.1232404] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
25 Li S, Wei Q, Li Q, Zhang B, Xiao Q. Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer. Cancer Biol Ther 2015;16:866-75. [PMID: 25920936 DOI: 10.1080/15384047.2015.1040958] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
26 Cowherd S, Miller LD, Melin SA, Akman S, Isom S, Cole J, Pullikuth A, Lawrence JA. A phase II clinical trial of weekly paclitaxel and carboplatin in combination with panitumumab in metastatic triple negative breast cancer. Cancer Biol Ther 2015;16:678-83. [PMID: 25928118 DOI: 10.1080/15384047.2015.1026481] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.6] [Reference Citation Analysis]
27 Amoury M, Mladenov R, Nachreiner T, Pham A, Hristodorov D, Di Fiore S, Helfrich W, Pardo A, Fey G, Schwenkert M, Thepen T, Kiessling F, Hussain AF, Fischer R, Kolberg K, Barth S. A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein: Anti-TNBC activity of a human CSPG4-specific human CFP. Int J Cancer 2016;139:916-27. [DOI: 10.1002/ijc.30119] [Cited by in Crossref: 19] [Cited by in F6Publishing: 21] [Article Influence: 3.8] [Reference Citation Analysis]
28 Pacheco-velázquez SC, Robledo-cadena DX, Hernández-reséndiz I, Gallardo-pérez JC, Moreno-sánchez R, Rodríguez-enríquez S. Energy Metabolism Drugs Block Triple Negative Breast Metastatic Cancer Cell Phenotype. Mol Pharmaceutics 2018;15:2151-64. [DOI: 10.1021/acs.molpharmaceut.8b00015] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 4.3] [Reference Citation Analysis]
29 Zheng W, Han S, Jiang S, He X, Li X, Ding H, Cao M, Li P. Antitumor effects of Xi Huang pills on MDA‑MB‑231 cells in vitro and in vivo. Mol Med Rep 2018;18:2068-78. [PMID: 29956784 DOI: 10.3892/mmr.2018.9203] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
30 Razmi M, Rabbani-chadegani A, Hashemi-niasari F, Ghadam P. Lithium chloride attenuates mitomycin C induced necrotic cell death in MDA-MB-231 breast cancer cells via HMGB1 and Bax signaling. Journal of Trace Elements in Medicine and Biology 2018;48:87-96. [DOI: 10.1016/j.jtemb.2018.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
31 Azzam H, Kamal R, El-assaly H, Metwally LIA. The value of dynamic contrast-enhanced MRI in differentiating triple-negative breast cancer from other subtypes. Egypt J Radiol Nucl Med 2019;50. [DOI: 10.1186/s43055-019-0118-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
32 Xu YL, Yao R, Li J, Zhou YD, Mao F, Pan B, Sun Q. FOXC1 overexpression is a marker of poor response to anthracycline-based adjuvant chemotherapy in sporadic triple-negative breast cancer. Cancer Chemother Pharmacol 2017;79:1205-13. [PMID: 28493031 DOI: 10.1007/s00280-017-3319-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 3.5] [Reference Citation Analysis]
33 Hussain MK, Singh DK, Singh A, Asad M, Ansari MI, Shameem M, Krishna S, Valicherla GR, Makadia V, Meena S, Deshmukh AL, Gayen JR, Imran Siddiqi M, Datta D, Hajela K, Banerjee D. A Novel Benzocoumarin-Stilbene Hybrid as a DNA ligase I inhibitor with in vitro and in vivo anti-tumor activity in breast cancer models. Sci Rep 2017;7:10715. [PMID: 28878282 DOI: 10.1038/s41598-017-10864-3] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
34 Masood S. Breast cancer subtypes: morphologic and biologic characterization. Womens Health (Lond) 2016;12:103-19. [PMID: 26756229 DOI: 10.2217/whe.15.99] [Cited by in Crossref: 9] [Cited by in F6Publishing: 13] [Article Influence: 1.8] [Reference Citation Analysis]
35 Bassey-Archibong BI, Rayner LG, Hercules SM, Aarts CW, Dvorkin-Gheva A, Bramson JL, Hassell JA, Daniel JM. Kaiso depletion attenuates the growth and survival of triple negative breast cancer cells. Cell Death Dis 2017;8:e2689. [PMID: 28333150 DOI: 10.1038/cddis.2017.92] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
36 Ahmed K, Koval A, Xu J, Bodmer A, Katanaev VL. Towards the first targeted therapy for triple-negative breast cancer: Repositioning of clofazimine as a chemotherapy-compatible selective Wnt pathway inhibitor. Cancer Lett 2019;449:45-55. [PMID: 30771433 DOI: 10.1016/j.canlet.2019.02.018] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 9.5] [Reference Citation Analysis]
37 Huang SP, Liu PY, Kuo CJ, Chen CL, Lee WJ, Tsai YH, Lin YF. The Gαh-PLCδ1 signaling axis drives metastatic progression in triple-negative breast cancer. J Hematol Oncol 2017;10:114. [PMID: 28576130 DOI: 10.1186/s13045-017-0481-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
38 Krohe M, Hao Y, Lamoureux RE, Galipeau N, Globe D, Foley C, Mazar I, Solomon J, Shields AL. Patient-Reported Outcomes in Metastatic Breast Cancer: A Review of Industry-Sponsored Clinical Trials. Breast Cancer (Auckl) 2016;10:93-102. [PMID: 27441001 DOI: 10.4137/BCBCR.S39385] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
39 Khatun Z, Nurunnabi M, Nafiujjaman M, Reeck GR, Khan HA, Cho KJ, Lee YK. A hyaluronic acid nanogel for photo-chemo theranostics of lung cancer with simultaneous light-responsive controlled release of doxorubicin. Nanoscale 2015;7:10680-9. [PMID: 26030737 DOI: 10.1039/c5nr01075f] [Cited by in Crossref: 78] [Cited by in F6Publishing: 25] [Article Influence: 13.0] [Reference Citation Analysis]
40 Sicchieri RD, da Silveira WA, Mandarano LRM, Gonçalves de Oliveira TM, Carrara HHA, Muglia VF, de Andrade JM, Tiezzi DG. ABCG2 is a potential marker of tumor-initiating cells in breast cancer. Tumor Biol 2015;36:9233-43. [DOI: 10.1007/s13277-015-3647-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
41 Yip C, Foidart P, Somja J, Truong A, Lienard M, Feyereisen E, Schroeder H, Gofflot S, Donneau AF, Collignon J, Delvenne P, Sounni NE, Jerusalem G, Noël A. MT4-MMP and EGFR expression levels are key biomarkers for breast cancer patient response to chemotherapy and erlotinib. Br J Cancer 2017;116:742-51. [PMID: 28196064 DOI: 10.1038/bjc.2017.23] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
42 Jin Z, Wang W, Jiang N, Zhang L, Li Y, Xu X, Cai S, Wei L, Liu X, Chen G, Zhou Y, Liu C, Li Z, Jin F, Chen B. Clinical Implications of iNOS Levels in Triple-Negative Breast Cancer Responding to Neoadjuvant Chemotherapy. PLoS One 2015;10:e0130286. [PMID: 26196284 DOI: 10.1371/journal.pone.0130286] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
43 O'Rorke MA, Murray LJ, Brand JS, Bhoo-Pathy N. The value of adjuvant radiotherapy on survival and recurrence in triple-negative breast cancer: A systematic review and meta-analysis of 5507 patients. Cancer Treat Rev 2016;47:12-21. [PMID: 27214603 DOI: 10.1016/j.ctrv.2016.05.001] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 4.2] [Reference Citation Analysis]
44 Israel BB, Tilghman SL, Parker-Lemieux K, Payton-Stewart F. Phytochemicals: Current strategies for treating breast cancer. Oncol Lett 2018;15:7471-8. [PMID: 29755596 DOI: 10.3892/ol.2018.8304] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
45 Zhou Y, Han C, Li D, Yu Z, Li F, Li F, An Q, Bai H, Zhang X, Duan Z, Kan Q. Cyclin-dependent kinase 11(p110) (CDK11(p110)) is crucial for human breast cancer cell proliferation and growth. Sci Rep 2015;5:10433. [PMID: 25990212 DOI: 10.1038/srep10433] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 5.2] [Reference Citation Analysis]
46 Hanafy NAN, Leporatti S, El-Kemary MA. Extraction of chlorophyll and carotenoids loaded into chitosan as potential targeted therapy and bio imaging agents for breast carcinoma. Int J Biol Macromol 2021;182:1150-60. [PMID: 33865895 DOI: 10.1016/j.ijbiomac.2021.03.189] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
47 Yu S, Cai X, Wu C, Liu Y, Zhang J, Gong X, Wang X, Wu X, Zhu T, Mo L, Gu J, Yu Z, Chen J, Thiery JP, Chai R, Chen L. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer. Int J Biol Sci 2017;13:505-17. [PMID: 28529458 DOI: 10.7150/ijbs.18834] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 4.5] [Reference Citation Analysis]
48 Heublein S, Mayr D, Meindl A, Kircher A, Jeschke U, Ditsch N. Vitamin D receptor, Retinoid X receptor and peroxisome proliferator-activated receptor γ are overexpressed in BRCA1 mutated breast cancer and predict prognosis. J Exp Clin Cancer Res 2017;36:57. [PMID: 28427429 DOI: 10.1186/s13046-017-0517-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
49 Masood S. The changing role of pathologists from morphologists to molecular pathologists in the era of precision medicine. Breast J 2020;26:27-34. [PMID: 31876097 DOI: 10.1111/tbj.13728] [Reference Citation Analysis]
50 Absmaier M, Napieralski R, Schuster T, Aubele M, Walch A, Magdolen V, Dorn J, Gross E, Harbeck N, Noske A, Kiechle M, Schmitt M. PITX2 DNA-methylation predicts response to anthracycline-based adjuvant chemotherapy in triple-negative breast cancer patients. Int J Oncol 2018;52:755-67. [PMID: 29328369 DOI: 10.3892/ijo.2018.4241] [Cited by in Crossref: 5] [Cited by in F6Publishing: 10] [Article Influence: 1.7] [Reference Citation Analysis]
51 Li A, Zhao Y, Li Y, Jiang L, Gu Y, Liu J. Cell-derived biomimetic nanocarriers for targeted cancer therapy: cell membranes and extracellular vesicles. Drug Deliv 2021;28:1237-55. [PMID: 34142930 DOI: 10.1080/10717544.2021.1938757] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
52 Khushi M, Clarke CL, Graham JD. Bioinformatic analysis of cis-regulatory interactions between progesterone and estrogen receptors in breast cancer. PeerJ 2014;2:e654. [PMID: 25426335 DOI: 10.7717/peerj.654] [Cited by in Crossref: 10] [Cited by in F6Publishing: 2] [Article Influence: 1.4] [Reference Citation Analysis]
53 Wang K, Zhu X, Zhang K, Yin Y, Chen Y, Zhang T. Interleukin-6 contributes to chemoresistance in MDA-MB-231 cells via targeting HIF-1α. J Biochem Mol Toxicol 2018;32:e22039. [PMID: 29341321 DOI: 10.1002/jbt.22039] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 6.3] [Reference Citation Analysis]
54 Johannessen C, Moi L, Kiselev Y, Pedersen MI, Dalen SM, Braaten T, Busund LT. Expression and function of the miR-143/145 cluster in vitro and in vivo in human breast cancer. PLoS One 2017;12:e0186658. [PMID: 29073169 DOI: 10.1371/journal.pone.0186658] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 6.0] [Reference Citation Analysis]
55 Mohamed HT, El-Ghonaimy EA, El-Shinawi M, Hosney M, Götte M, Woodward WA, El-Mamlouk T, Mohamed MM. IL-8 and MCP-1/CCL2 regulate proteolytic activity in triple negative inflammatory breast cancer a mechanism that might be modulated by Src and Erk1/2. Toxicol Appl Pharmacol 2020;401:115092. [PMID: 32512068 DOI: 10.1016/j.taap.2020.115092] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
56 Guardiola-Serrano F, Beteta-Göbel R, Rodríguez-Lorca R, Ibarguren M, López DJ, Terés S, Alonso-Sande M, Higuera M, Torres M, Busquets X, Escribá PV. The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt. Oncotarget 2019;10:2486-507. [PMID: 31069012 DOI: 10.18632/oncotarget.26824] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
57 O'Brien K, Lowry MC, Corcoran C, Martinez VG, Daly M, Rani S, Gallagher WM, Radomski MW, MacLeod RA, O'Driscoll L. miR-134 in extracellular vesicles reduces triple-negative breast cancer aggression and increases drug sensitivity. Oncotarget 2015;6:32774-89. [PMID: 26416415 DOI: 10.18632/oncotarget.5192] [Cited by in Crossref: 123] [Cited by in F6Publishing: 131] [Article Influence: 24.6] [Reference Citation Analysis]
58 Powell CA, Nasser MW, Zhao H, Wochna JC, Zhang X, Shapiro C, Shilo K, Ganju RK. Fatty acid binding protein 5 promotes metastatic potential of triple negative breast cancer cells through enhancing epidermal growth factor receptor stability. Oncotarget 2015;6:6373-85. [PMID: 25779666 DOI: 10.18632/oncotarget.3442] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 5.6] [Reference Citation Analysis]
59 Guney Eskiler G, Cecener G, Egeli U, Tunca B. Triple negative breast cancer: new therapeutic approaches and BRCA status. APMIS 2018;126:371-9. [DOI: 10.1111/apm.12836] [Cited by in Crossref: 24] [Cited by in F6Publishing: 18] [Article Influence: 8.0] [Reference Citation Analysis]
60 Longo A, Librizzi M, Chuckowree IS, Baltus CB, Spencer J, Luparello C. Cytotoxicity of the Urokinase-Plasminogen Activator Inhibitor Carbamimidothioic Acid (4-Boronophenyl) Methyl Ester Hydrobromide (BC-11) on Triple-Negative MDA-MB231 Breast Cancer Cells. Molecules 2015;20:9879-89. [PMID: 26029857 DOI: 10.3390/molecules20069879] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
61 Amirkhani Namagerdi A, d'Angelo D, Ciani F, Iannuzzi CA, Napolitano F, Avallone L, De Laurentiis M, Giordano A. Triple-Negative Breast Cancer Comparison With Canine Mammary Tumors From Light Microscopy to Molecular Pathology. Front Oncol 2020;10:563779. [PMID: 33282730 DOI: 10.3389/fonc.2020.563779] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Chen J, Qin Y, Sun C, Hao W, Zhang S, Wang Y, Chen J, Chen L, Ruan Y, Liu S. Clinical study on postoperative triple-negative breast cancer with Chinese medicine: Study protocol for an observational cohort trial. Medicine (Baltimore) 2018;97:e11061. [PMID: 29923998 DOI: 10.1097/MD.0000000000011061] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
63 Wang F, Song X, Ma S, Liu C, Sun X, Wang X, Liu Z, Liang D, Yu Z. The treatment role of Cyperus rotundus L. to triple-negative breast cancer cells. Biosci Rep 2019;39:BSR20190502. [PMID: 31123166 DOI: 10.1042/BSR20190502] [Cited by in Crossref: 6] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
64 Zhang XL, Liu N, Weng SF, Wang HS. Bisphenol A Increases the Migration and Invasion of Triple-Negative Breast Cancer Cells via Oestrogen-related Receptor Gamma. Basic Clin Pharmacol Toxicol 2016;119:389-95. [PMID: 27038254 DOI: 10.1111/bcpt.12591] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 5.4] [Reference Citation Analysis]
65 Labbozzetta M, Notarbartolo M, Poma P. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View. Int J Mol Sci 2020;21:E3070. [PMID: 32349210 DOI: 10.3390/ijms21093070] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 7.0] [Reference Citation Analysis]
66 Ge L, Tang Y, Zhang QN, Tian JH, Wang XH, Pieper D, Pan B, Li L, Ling J, Bing ZT, Yang KH. A network meta-analysis on the efficacy of targeted agents in combination with chemotherapy for treatment of advanced/metastatic triple-negative breast cancer. Oncotarget 2017;8:59539-51. [PMID: 28938657 DOI: 10.18632/oncotarget.19102] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
67 Zheng W, Han S, Jiang S, Pang L, Li X, Liu X, Cao M, Li P. Multiple effects of Xihuang pill aqueous extract on the Hs578T triple-negative breast cancer cell line. Biomed Rep 2016;5:559-66. [PMID: 27882217 DOI: 10.3892/br.2016.769] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]